AAP
VYGR icon

Arax Advisory Partners’s Voyager Therapeutics VYGR Stock Holding History

Arax Advisory Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.2K Buy
13,203
+13,155
+27,406% +$49.9K ﹤0.01% 3334
2026
Q1 		$185 Sell
48
-323
-87% -$1.27K ﹤0.01% 3554
2025
Q4 		$1.46K Sell
371
-1,253
-77% -$5.54K ﹤0.01% 3378
2025
Q3 		$7.58K Buy
+1,624
New +$5.88K ﹤0.01% 2715
2024
Q4 		– Sell
-411
Closed -$2.4K – 2770
2024
Q3 		$2.4K Hold
411
– – ﹤0.01% 1995
2024
Q2 		$3.25K Buy
+411
New +$3.45K ﹤0.01% 1791

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Arax Advisory Partners's VYGR Position: Q2 2026 in Review

Arax Advisory Partners increased its Voyager Therapeutics (VYGR) stake by 27,406% in Q2 2026, buying an estimated $49.9K and bringing the position to 13,203 shares worth $46.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3334.

Arax Advisory Partners first reported a position in VYGR in Q2 2024 and has held it in 6 quarters since. 135 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Arax Advisory Partners held 13,203 shares of Voyager Therapeutics worth $46.2K as of Q2 2026.
  • Arax Advisory Partners bought 13,155 Voyager Therapeutics shares in Q2 2026, an estimated $49.9K.
  • Voyager Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3334 holding.
  • Arax Advisory Partners first reported a position in Voyager Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.